A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.
Goel S, Desai K, Bulgaru A, Fields A, Goldberg G, Agrawal S, Martin R, Grindel M, Mani S. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clinical Cancer Research 2003, 9: 4069-76. PMID: 14519628.Peer-Reviewed Original ResearchAgedAged, 80 and overCyclic AMP-Dependent Protein KinasesFemaleHematologic DiseasesHumansInfusions, IntravenousMaleMiddle AgedNeoplasmsOligonucleotidesProtein Subunits